Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905335 | 1.00 | RORC (0.44) | RORCIDO1SLC22A12HTTTRPV4 | |
| SCHEMBL5174565 | 0.92 | ALDH1A1 (0.41) | RORCIDO1SLC22A12HTTTRPV4 | |
| SCHEMBL18552774 | 0.84 | IDO1 (0.48) | RORCIDO1SLC22A12TRPV4AR | |
| SCHEMBL4901833 | 0.79 | AR (0.48) | RORCSLC22A12AR | |
| SCHEMBL4903923 | 0.79 | AR (0.48) | RORCSLC22A12AR | |
| SCHEMBL4905185 | 0.79 | AR (0.48) | RORCSLC22A12AR | |
| SCHEMBL4904652 | 0.79 | ALDH1A1 (0.52) | RORCIDO1SLC22A12HTTTRPV4 | |
| SCHEMBL4904656 | 0.79 | ALDH1A1 (0.52) | RORCIDO1SLC22A12HTTTRPV4 | |
| SCHEMBL18528094 | 0.77 | MAP3K8 (0.48) | RORCIDO1SLC22A12HTTTRPV4 | |
| SCHEMBL18528092 | 0.77 | MAP3K8 (0.48) | RORCIDO1SLC22A12HTTTRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | claimed |
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2006024931-A2 | THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | TNNC1, TNNI3, TNNT2 | RORC 3357/4885IDO1 1307/4885SLC22A12 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.